Acarbose and Farxiga drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Acarbose and Farxiga. Common interactions include blood methanol increased among females and death among males.

The phase IV clinical study analyzes what interactions people who take Acarbose and Farxiga have. It is created by eHealthMe based on reports of 9 people who take Acarbose and Farxiga from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Oct, 03, 2022

9 people who take Acarbose and Farxiga together, and have interactions are studied.


What is Acarbose?

Acarbose has active ingredients of acarbose. It is often used in diabetes. eHealthMe is studying from 4,047 Acarbose users for its effectiveness, alternative drugs and more.

What is Farxiga?

Farxiga has active ingredients of dapagliflozin. It is often used in diabetes. eHealthMe is studying from 10,699 Farxiga users for its effectiveness, alternative drugs and more.

Number of Acarbose and Farxiga reports submitted per year:

Acarbose and Farxiga drug interactions.

Common Acarbose and Farxiga drug interactions by gender *:

female:

  1. Blood methanol increased
  2. Body height decreased
  3. Carpal tunnel syndrome
  4. Contusion
  5. Drug ineffective
  6. Headache
  7. Hypoacusis
  8. Infection
  9. Injection site extravasation
  10. Injection site nodule

male:

  1. Death
  2. Hip disarticulation
  3. Septic shock
  4. Urinary tract infection

Common Acarbose and Farxiga drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Blood methanol increased
  2. Headache
  3. Nausea

50-59:

  1. Hip disarticulation
  2. Septic shock
  3. Urinary tract infection
  4. Diabetic ketoacidosis
  5. Diabetic neuropathy
  6. Abdominal distension
  7. Blood glucose decreased
  8. Carpal tunnel syndrome
  9. Injection site extravasation
  10. Injection site nodule

60+:

  1. Body height decreased
  2. Contusion
  3. Visual impairment
  4. Weight increased
  5. Death
  6. Drug ineffective
  7. Hypoacusis
  8. Infection
  9. Lower limb fracture
  10. Musculoskeletal disorder

* Approximation only. Some reports may have incomplete information.

Do you take Acarbose and Farxiga?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Acarbose and Farxiga:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Acarbose interactions:

Browse all interactions between Acarbose and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Farxiga interactions:

Browse all interactions between Farxiga and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on acarbose and dapagliflozin (the active ingredients of Acarbose and Farxiga, respectively), and Acarbose and Farxiga (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Acarbose and Farxiga.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: